Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Neurocrine Bioscienc (NQ: NBIX )

123.98 -1.32 (-1.05%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neurocrine Bioscienc

< Previous 1 2 3 4 5 6 7 8 9 Next >
In-Depth Examination Of 20 Analyst Recommendations For Neurocrine Biosciences
Via Benzinga
NASDAQ:NBIX stands out as a growth opportunity that won't break the bank.
Investors should take note of NASDAQ:NBIX, a growth stock that remains attractively priced. 
Via Chartmill
NASDAQ:NBIX appears to be flying under the radar despite its strong fundamentals.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. 
Via Chartmill
Why NASDAQ:NBIX Is a Promising High-Growth Stock in the Midst of Consolidation.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
Via Chartmill
Critical Insights From Neurocrine Biosciences Analyst Ratings: What You Need To Know
Via Benzinga
"Rule Breaker Investing" Market Cap Game Show: Throwdowns & Long-Term Wins
Motley Fool analysts Matt Argersinger and Yasser El-Shimy face off. 
Via The Motley Fool
NASDAQ:NBIX—A High-Growth Stock Gearing Up for Its Next Upward Move.
Why NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Is a Standout High-Growth Stock in a Consolidation Phase. 
Via Chartmill
Decoding 19 Analyst Evaluations For Neurocrine Biosciences
Via Benzinga
NASDAQ:NBIX, a growth stock which is not overvalued.
Investors should take note of NASDAQ:NBIX, a growth stock that remains attractively priced. 
Via Chartmill
Despite its growth, NASDAQ:NBIX remains within the realm of affordability.
In the world of growth stocks, NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) shines as a value proposition. 
Via Chartmill
For those who appreciate value investing, NASDAQ:NBIX is a compelling option with its solid fundamentals.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is probably undervalued for the fundamentals it is displaying. 
Via Chartmill
Neurocrine Shifts Focus To New Schizophrenia Treatment After Luvadaxistat Trial Misses Endpoint
Neurocrine Biosciences announced that its ERUDITE Phase 2 trial for luvadaxistat failed to meet its primary endpoint in treating cognitive impairment in schizophrenia. The company will halt development... 
Via Benzinga
Intel, Moderna And Dollar General Were Among Top 10 Large Cap Losers In August: Are The Others In Your Portfolio?
10 worst performing large-cap stocks in August: Super Micro, Dollar General, Snap, PDD Holdings, Intel, Tencent Music, Gold Fields, Charles River, Moderna, Neurocrine Biosciences. 
Via Benzinga
Don't overlook NASDAQ:NBIX—it's a hidden gem with strong fundamentals and an attractive price tag.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) stands out as a stock that provides good value for the fundamentals it showcases. 
Via Chartmill
Evaluating Neurocrine Biosciences: Insights From 15 Financial Analysts
Via Benzinga
NASDAQ:NBIX—A High-Growth Stock Gearing Up for Its Next Upward Move.
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX): a strong growth stock preparing for the next leg up?. 
Via Chartmill
NASDAQ:NBIX is not too expensive for the growth it is showing.
Don't overlook NASDAQ:NBIX—a stock with solid growth prospects and a reasonable valuation. 
Via Chartmill
Dollar General, Temu Parent PDD And Super Micro Computer Are Among Top 10 Large Cap Losers Last Week (Aug 25-Aug 31): Are The Others In Your Portfolio?
10 worst performing large-cap stocks in the last week. Dollar General, Super Micro Computer, Okta, Pure Storage, Neurocrine Biosciences among them. 
Via Benzinga
Stock Market Rally Mixed; Dow Jones Hits High While Nvidia Tumbles On Earnings: Weekly Review
The Dow Jones hit a new high while Nvidia led a Nasdaq retreat. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Why Neurocrine Biosciences Stock Was Tumbling This Week
The company promises to advance a top investigational drug to late-stage testing, but investors might not think that's a fine idea. 
Via The Motley Fool
Neurocrine Biosciences' Lower Dose Data Puts Its Schizophrenia Candidate In The Game, Analyst Upgrades Stock
Neurocrine Biosciences reports positive Phase 2 trial results for NBI-1117568 in adults with schizophrenia, showing significant reduction in PANSS scores with a 20 mg dose. Piper Sandler upgrades the... 
Via Benzinga
NVIDIA To Rally Over 31%? Here Are 10 Top Analyst Forecasts For Thursday
Via Benzinga
Nasdaq Down Over 1%; Foot Locker Shares Tumble After Q2 Results
Via Benzinga
As Regulators Gear Up To Decide On Bristol Myers' Schizophrenia Treatment, Neurocrine Biosciences' Data Disappoints Investors
Neurocrine Biosciences reports Phase 2 trial results for NBI-1117568 showing significant improvement in schizophrenia symptoms, with an 18.2-point reduction in PANSS scores at a 20 mg dose. 
Via Benzinga
US Stocks Mixed; JM Smucker Slashes Annual Guidance
Via Benzinga
Neurocrine Bio Dives As Schizophrenia Trial Results Lags Peers
As new schizophrenia drugs move toward approval, Neurocrine Biosciences reports a subpar outcome for its phase 2 trial. 
Via Investor's Business Daily
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
Drug companies are investing in schizophrenia treatments as patients are desperate for a drug that has few side effects, Bloomberg reports. 
Via Benzinga
Why the quality investor may take a look at NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX).
Is NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) suited for quality investing? 
Via Chartmill
9 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
New Study Reveals How Classical Music Could Revolutionize Depression Care
In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of... 
Via PressReach
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.